The anti-diabetic drug Canagliflozin protects against Myocardial Infarction and its associated complications: Canagliflozin (brand name: Invokana and Sulisent), a sodium -glucose co-transporter-2 inhibitor used in the treatment of TIIDM, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 18/April/2019, 6.50am

A derivative of male hormone Dihydrotestosterone (DHT)  boosts longevity: Dihydrotestosterone (DHT) slows down cardiac aging, and increases lifespan, via up-regulation of BubR1 and others genes, 17/April/2019, 11.28 pm
April 17, 2019
Intracardiac injection of Synthetic PreImplantation Factor (sPIF) promotes heart regeneration and repair: Intracardiac injection of Synthetic PreImplantation Factor (sPIF) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 18/April/2019, 8.01 am
April 18, 2019
Show all

What they say

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature (impact factor41.577) ,  by Prof Dimmler, Boon, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  The anti-diabetic drug Canagliflozin protects against Myocardial Infarction and its associated complications: Canagliflozin (brand name: Invokana and Sulisent), a sodium -glucose co-transporter-2 inhibitor used in the treatment of TIIDM, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS


price-300[easy_payment currency=”USD”]

From Significance of the study to Public Health Relevance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From Research Findings to Therapeutic Opportunity

I had suggested earlier ( on 15/November/2018 at 10.02 pm) that Canagliflozin  may protect against myocardial dysfunction (https://genomediscovery.org/2018/11/the-known-anti-hyperglycemic-agent-empagliflozin-empa-may-safeguard-your-heart-against-cardiac-dysfunction-empagliflozin-empa-a-drug-used-in-the-treatment-of-tiidm/).

Evidently, a very recent study from the the Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, the George Institute for Global Health, University of New South Wales Sydney, the Royal North Shore Hospital and others shows that “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. This study was published, in the 14 April 2019 issue of of the prestigious journal N Engl J Med. (NEJM) (Impact factor: 79.258+) ,  by Prof. Mahaffey KW, Perkovic V, Brenner BM and others. In concordance with what I stated earlier, this study suggests that Canagliflozin lowers the risk of heart failure.  However, the mechanism of action of this drug is not known yet. 

This study suggests, for the first time, that Canagliflozin, by increasing the expression of its target genes, it may increase the expression of PNUTS (fig.1). Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate aging; and (6) extend lifespan (fig 1). 

Figure 1.  Mechanistic insights into how Canagliflozin  induces the expression of PNUTS and Telomerase to prevent myocardial infarction and promote Cardiac regeneration/survival

Figure 2.Canagliflozin  functions as a cardioprotective agent through induction of PNUTS

Together, this study suggests that pharmacological formulations encompassing“Canagliflozin  or its analogs, either alone or in combination with other drugs,” may be used to improve cardiac function after myocardial infarction (fig. 2).  


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Canagliflozin increase the expression of PNUTS/Telomerase?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References

Web:http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L., The anti-diabetic drug Canagliflozin protects against Myocardial Infarction and its associated complications: Canagliflozin (brand name: Invokana and Sulisent), a sodium -glucose co-transporter-2 inhibitor used in the treatment of TIIDM, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 18/April/2019, 6.50 am,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.